PASSAGE BIO

Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PHILADELPHIA, March 22, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced it has appointed Eliseo O. Salinas, M.D., MSc, as the company's chief research & development (R&D) officer. Dr. Salinas joins the company from Acadia Pharmaceuticals, where he served as chief scientific officer (CSO) and senior vice president, External Innovation.

Passage Bio Appoints Eliseo O. Salinas, M.D.

FDA designation will facilitate development and expedited review of company's lead gene therapy product candidates for life-threatening diseases with unmet medical needs: PBGM01 for GM1 gangliosidosis (GM1), PBFT02 for frontotemporal dementia with granulin mutations, and PBKR03 for Krabbe disease FDA designation will facilitate development and expedited review of company's lead gene therapy product candidates for life-threatening diseases with unmet medical needs: PBGM01 for GM1 gangliosidosis (GM1), PBFT02 for frontotemporal dementia with granulin mutations, and PBKR03 for Krabbe disease

U.S. Food and Drug Administration Grants Fast Track Designation to Three Passage Bio Gene Therapy Candidates Targeting Rare CNS Disorders

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2020 Results - Earnings Call Transcript

- On track to initiate three Phase 1/2 clinical programs in the first half of 2021: PBGM01 for GM1 gangliosidosis (GM1), PBFT02 for frontotemporal dementia with granulin mutations, and PBKR03 for Krabbe disease - - Opened first U.S. site for PBGM01's Imagine-1 global clinical program and actively recruiting patients; other site activations in progress - - Opening new CMC research and development site to support analytics, assay development, and product testing in 2Q 2021 - - Strengthened financial position with recent public offering that raised $166M in net proceeds - - Management to host conference call today at 8:30 a.m. ET -

Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights

PHILADELPHIA, March 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming virtual investor conferences in March:

Passage Bio to Participate in Upcoming March Investor Conferences

Magenta Therapeutics Inc

MediciNova

Prevail Therapeutics Inc

Gain Therapeutics has filed to raise $40 million in a U.S. IPO.

Gain Therapeutics Aims For $40 Million IPO

PHILADELPHIA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 3, 2021 to report its fourth quarter and full-year 2020 financial results and discuss recent business highlights.

Passage Bio to Report Fourth Quarter and Full-Year 2020 Financial Results on March 3, 2021

PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced the appointment of Maxine Gowen, Ph.D., to its board of directors, effective Feb. 18. Dr. Gowen is chief executive officer of Tamuro Bio, a post that she has held since July 2019.

Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors

- Phase 1/2 trial expected to commence in first half of 2021

FDA Clears IND Application for Passage Bio's Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options

Passage Bio Inc (NASDAQ: PASG) is leveraging the UPenn Gene Therapy Program to access compelling translational research and develop a range of differentiated adeno-associated virus gene therapies for rare central nervous system disorders, according to Guggenheim. The Passage Bio Analyst: Debjit Chattopadhyay initiated coverage of Passage Bio with a Buy rating and $25 price target.

Why Guggenheim Is Bullish On Passage Bio

– Second Product Candidate Expected to Enter Clinic in First Half of 2021

Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations

The stock price of Passage Bio Inc (NASDAQ: PASG) as it went from a previous close of $22.82 to $19.81 fell 13.19%. This is why it happened.

PASG Stock Price Fell 13.19%: Why It Happened

A secondary offering will dilute shareholders.

Here's Why Shares of Passage Bio Dropped Today

PHILADELPHIA, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system disorders, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $22.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $154.0 million. All shares of common stock to be sold in the offering will be sold by Passage Bio. In addition, Passage Bio has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 26, 2021, subject to the satisfaction of customary closing conditions.

Passage Bio Announces Pricing of Public Offering

PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system disorders, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All shares of common stock to be sold in the offering will be sold by Passage Bio. In addition, Passage Bio intends to grant the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the public offering price, less underwriting discounts and commission. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Passage Bio Announces Launch of Proposed Public Offering

Phathom Pharmaceuticals

MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate. Aditya Kohli, Ph.D., joined the Frazier Life Sciences team in 2016 and focuses on company creation. He co-founded Phathom Pharmaceuticals (NASDAQ: PHAT) and Scout Bio, and helped launch Passage Bio (NASDAQ: PASG). Dr. Kohli serves as the Chief Business Officer of P

Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team

PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., president and chief executive officer will present a company overview at the J.P Morgan 39th Annual Healthcare Conference being held virtually on Monday, January 11, 2021 at 7:30am ET.

Passage Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study,  expected to dose first patient in first quarter 2021

Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis

- Company invests to build in-house capabilities to support advancement of pipeline -

Passage Bio Announces Gene Therapy Manufacturing Research and Development Site

- MHRA approval represents first clinical trial authorization for the global PBGM01 clinical trial program -

Passage Bio Receives MHRA Clinical Trial Authorization for PBGM01 for Treatment of GM1 Gangliosidosis

- Completion of dedicated CGMP suite enhances manufacturing readiness and secures supply chain control to support lead CNS gene therapy product candidates as they advance through clinical trials to commercialization - - Completion of dedicated CGMP suite enhances manufacturing readiness and secures supply chain control to support lead CNS gene therapy product candidates as they advance through clinical trials to commercialization -

Passage Bio Teams with Catalent to Start CGMP Manufacturing for Lead Gene Therapy Products

PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., chief executive officer of Passage Bio, will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference, taking place December 1 – 3, 2020.

Passage Bio to Present at Piper Sandler 32nd Annual Healthcare Conference

Through its unique collaboration agreement, Passage Bio has certain rights to technology highlighted in the University's research, which has the potential to significantly advance nascent field of gene therapy Through its unique collaboration agreement, Passage Bio has certain rights to technology highlighted in the University's research, which has the potential to significantly advance nascent field of gene therapy

Passage Bio Highlights University of Pennsylvania's Gene Therapy Program's Newly Published Research to Prevent Toxicity Associated with Gene Therapy

PHILADELPHIA, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming virtual investor conferences in November.

Passage Bio to Participate in Upcoming November Investor Conferences

Passage Bio, Inc. (PASG) CEO Karl Bruce Goldsmith on Q3 2020 Results - Earnings Call Transcript

News for PASSAGE BIO Stock (PASG)